Cipla receives warning letter from USFDA for Goa manufacturing facility

26 Feb 2020 Evaluate

Cipla has received a warning letter from the United States Food and Drug Administration (USFDA) for its Goa manufacturing facility. The USFDA had conducted inspection from September 16, 2019 to September 27, 2019.The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×